再探脓毒症中的抗凝血酶。
Antithrombin in sepsis revisited.
作者信息
Levi Marcel
机构信息
Department of Vascular Medicine and Internal Medicine, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands.
出版信息
Crit Care. 2005;9(6):624-5. doi: 10.1186/cc3819. Epub 2005 Sep 26.
Abstract
As the pivotal phase III randomized controlled clinical trial on antithrombin concentrate in patients with severe sepsis did not show a beneficial effect of antithrombin treatment on 28-day mortality, the interest in the potential use of this treatment modality in sepsis has diminished. However, recent data on the effect of antithrombin administration on coagulation in combination with recent analyses from the clinical trials that were aimed to restore physiological anticoagulant pathways in patients with sepsis may revitalize the interest in antithrombin concentrate for the treatment of severe sepsis.
摘要
由于关于抗凝血酶浓缩物用于严重脓毒症患者的关键III期随机对照临床试验未显示抗凝血酶治疗对28天死亡率有有益影响，对这种治疗方式在脓毒症中潜在应用的兴趣已经减弱。然而，近期关于抗凝血酶给药对凝血影响的数据，以及旨在恢复脓毒症患者生理抗凝途径的临床试验的最新分析，可能会重新激发人们对使用抗凝血酶浓缩物治疗严重脓毒症的兴趣。
相似文献
1
Antithrombin in sepsis revisited.再探脓毒症中的抗凝血酶。
Crit Care. 2005;9(6):624-5. doi: 10.1186/cc3819. Epub 2005 Sep 26.
2
Reduction of D-dimer levels after therapeutic administration of antithrombin in acquired antithrombin deficiency of severe sepsis.在严重脓毒症获得性抗凝血酶缺乏症中，抗凝血酶治疗性给药后D-二聚体水平的降低。
Crit Care. 2005;9(6):R596-600. doi: 10.1186/cc3808. Epub 2005 Sep 19.
3
Sepsis, coagulation, and antithrombin: old lessons and new insights.脓毒症、凝血与抗凝血酶：旧识与新知
Semin Thromb Hemost. 2008 Nov;34(8):742-6. doi: 10.1055/s-0029-1145256. Epub 2009 Feb 12.
4
Antithrombin concentrate use in sepsis-associated disseminated intravascular coagulation: re-evaluation of a 'pendulum effect' drug using a nationwide database.抗凝血酶浓缩物在脓毒症相关性弥散性血管内凝血中的应用：使用全国性数据库重新评估一种“钟摆效应”药物。
J Thromb Haemost. 2018 Mar;16(3):458-461. doi: 10.1111/jth.13948. Epub 2018 Jan 29.
5
Antithrombin substitution therapy.抗凝血酶替代疗法。
Blood Coagul Fibrinolysis. 1998 Nov;9 Suppl 3:S17-21; discussion S21-2.
6
The anticoagulant therapy for sepsis-associated disseminated intravascular coagulation.脓毒症相关性弥散性血管内凝血的抗凝治疗。
Thromb Res. 2013 May;131(5):383-9. doi: 10.1016/j.thromres.2013.03.012. Epub 2013 Apr 6.
7
Effects of antithrombin and gabexate mesilate on disseminated intravascular coagulation: a preliminary study.抗凝血酶和甲磺酸加贝酯对弥漫性血管内凝血的影响：初步研究。
Am J Emerg Med. 2012 Sep;30(7):1219-23. doi: 10.1016/j.ajem.2011.06.003. Epub 2011 Dec 26.
8
Antithrombin concentrate use in disseminated intravascular coagulation of sepsis: meta-analyses revisited.抗凝血酶浓缩物在脓毒症弥漫性血管内凝血中的应用：重新审视荟萃分析。
J Thromb Haemost. 2018 Mar;16(3):455-457. doi: 10.1111/jth.13950. Epub 2018 Feb 19.
9
Anticoagulant factor concentrates in disseminated intravascular coagulation: rationale for use and clinical experience.弥散性血管内凝血中抗凝因子浓缩物：使用原理及临床经验
Semin Thromb Hemost. 2001 Dec;27(6):667-74. doi: 10.1055/s-2001-18871.
10
High-dose antithrombin therapy for sepsis.用于脓毒症的高剂量抗凝血酶疗法。
J Trauma. 2000 Nov;49(5):979-80. doi: 10.1097/00005373-200011000-00034.
引用本文的文献
1
Platelets, Bacterial Adhesins and the Pneumococcus.血小板、细菌黏附素与肺炎球菌
Cells. 2022 Mar 25;11(7):1121. doi: 10.3390/cells11071121.
2
Sepsis-Associated Coagulopathy.脓毒症相关凝血病
J Crit Care Med (Targu Mures). 2016 Nov 8;2(4):156-163. doi: 10.1515/jccm-2016-0024. eCollection 2016 Oct.
3
Systemic versus localized coagulation activation contributing to organ failure in critically ill patients.全身性与局部性凝血激活导致危重症患者器官衰竭。
Semin Immunopathol. 2012 Jan;34(1):167-79. doi: 10.1007/s00281-011-0283-7. Epub 2011 Jul 30.
4
Recommendations for the use of antithrombin concentrates and prothrombin complex concentrates.抗凝血酶浓缩物和凝血酶原复合物浓缩物的使用建议。
Blood Transfus. 2009 Oct;7(4):325-34. doi: 10.2450/2009.0116-09.
5
Clinical review: molecular mechanisms underlying the role of antithrombin in sepsis.临床综述：抗凝血酶在脓毒症中作用的分子机制
Crit Care. 2006 Feb;10(1):209. doi: 10.1186/cc4822.
本文引用的文献
1
Reduction of D-dimer levels after therapeutic administration of antithrombin in acquired antithrombin deficiency of severe sepsis.在严重脓毒症获得性抗凝血酶缺乏症中，抗凝血酶治疗性给药后D-二聚体水平的降低。
Crit Care. 2005;9(6):R596-600. doi: 10.1186/cc3808. Epub 2005 Sep 19.
2
Treatment effects of drotrecogin alfa (activated) in patients with severe sepsis with or without overt disseminated intravascular coagulation.重组人活化蛋白C对伴或不伴明显弥散性血管内凝血的严重脓毒症患者的治疗效果
J Thromb Haemost. 2004 Nov;2(11):1924-33. doi: 10.1111/j.1538-7836.2004.00955.x.
3
Bidirectional relation between inflammation and coagulation.炎症与凝血之间的双向关系。
Circulation. 2004 Jun 8;109(22):2698-704. doi: 10.1161/01.CIR.0000131660.51520.9A.
4
Towards definition, clinical and laboratory criteria, and a scoring system for disseminated intravascular coagulation.关于弥散性血管内凝血的定义、临床及实验室标准和评分系统
Thromb Haemost. 2001 Nov;86(5):1327-30.
5
Safety and dose relationship of recombinant human activated protein C for coagulopathy in severe sepsis.重组人活化蛋白C用于严重脓毒症凝血病的安全性及剂量关系
Crit Care Med. 2001 Nov;29(11):2051-9. doi: 10.1097/00003246-200111000-00003.
6
Caring for the critically ill patient. High-dose antithrombin III in severe sepsis: a randomized controlled trial.重症患者的护理。严重脓毒症中高剂量抗凝血酶III：一项随机对照试验。
JAMA. 2001 Oct 17;286(15):1869-78. doi: 10.1001/jama.286.15.1869.
7
Role of coagulation inhibitors in inflammation.凝血抑制剂在炎症中的作用。
Thromb Haemost. 2001 Jul;86(1):51-6.
8
Rationale for restoration of physiological anticoagulant pathways in patients with sepsis and disseminated intravascular coagulation.脓毒症和弥散性血管内凝血患者恢复生理性抗凝途径的理论依据。
Crit Care Med. 2001 Jul;29(7 Suppl):S90-4. doi: 10.1097/00003246-200107001-00028.
9
Efficacy and safety of recombinant human activated protein C for severe sepsis.重组人活化蛋白C治疗严重脓毒症的疗效与安全性
N Engl J Med. 2001 Mar 8;344(10):699-709. doi: 10.1056/NEJM200103083441001.
Zotero 插件